Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Nephrology/Urology

Renal Cell Carcinoma

California

Duarte : City of Hope

CTSU/ECOG E2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

Colorado

Denver : The Urology Center of Colorado

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Georgia

Atlanta : Emory University

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Illinois

Elgin : Sherman Health Systems

Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Elgin : Sherman Health Systems

The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR

Indiana

Beech Grove : St. Francis Hospital and Health Centers

Study VEG108844, a Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Indianapolis : The Indiana Cancer Center

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Iowa

Iowa City : University of Iowa

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Kansas

Kansas City : University of Kansas Hospital

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Minnesota

Minneapolis : University of Minnesota Cancer Center

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

New Hampshire

Lebanon : Dartmouth-Hitchcock Medical Center

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

New York

Manhasset : Biomedical Research Alliance of New York

A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear cell renal cell carcinoma and a high risk of recurrence

Manhasset : Biomedical Research Alliance of New York, LLC

Study for high risk recurrence of renal cell carcinoma after surgical treatment

New York : Mount Sinai Medical Center

A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage? Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma.

North Carolina

Charlotte : Blumenthal Cancer Center

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Texas

Dallas : CORTPA

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Virginia

Charlottesville : University of Virginia New!

Men and Women ages 18 and over with untreated advanced renal cell carcinoma needed for a research study.

Canada

Montreal, QC : Jewish General Hospital

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib

Toronto, ON : Princess Margaret Hospital

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib